Multiple Sclerosis Journal

Journal

Publication Venue For

  • The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.  28:1783-1792. 2022
  • The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.  28:1606-1619. 2022
  • Gene–environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.  28:1330-1339. 2022
  • Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.  28:1286-1298. 2022
  • Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.  28:1091-1100. 2022
  • MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.  28:561-572. 2022
  • Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.  28:790-800. 2022
  • The timed 25-foot walk in a large cohort of multiple sclerosis patients.  28:289-299. 2022
  • Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS 2022
  • Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.  27:2052-2061. 2021
  • A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.  27:1864-1874. 2021
  • An enrichment strategy for clinical trials in SPMS.  27:1884-1893. 2021
  • Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.  27:1781-1789. 2021
  • New applications for independent activities of daily living in measuring disability in multiple sclerosis.  27:97-106. 2021
  • Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.  26:1938-1947. 2020
  • Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets.  26:1540-1549. 2020
  • Aggressive multiple sclerosis (1): Towards a definition of the phenotype.  26:1031-1044. 2020
  • Aggressive multiple sclerosis (2): Treatment.  26:1045-1063. 2020
  • Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.  26:1102-1110. 2020
  • Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.  26:976-986. 2020
  • Vitamin D genes influence MS relapses in children.  26:894-901. 2020
  • Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.  25:837-847. 2019
  • Genetic risk factors for pediatric-onset multiple sclerosis.  24:1825-1834. 2018
  • The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.  24:1469-1484. 2018
  • Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.  24:1288-1300. 2018
  • Dietary factors and pediatric multiple sclerosis: A case-control study.  24:1067-1076. 2018
  • A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.  24:951-962. 2018
  • Clinical trial design for progressive MS trials.  23:1642-1648. 2017
  • Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.  23:982-987. 2017
  • Declines in the diagnosis of primary progressive MS: A critical change in phenotype or critical measurement error?.  22:983-985. 2016
  • Placebo-controlled study in neuromyelitis optica - Ethical and design considerations.  22:862-872. 2016
  • A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.  21:282-293. 2015
  • A systematic review of the incidence and prevalence of cancer in multiple sclerosis.  21:294-304. 2015
  • A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis.  21:318-331. 2015
  • A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview.  21:263-281. 2015
  • A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.  21:342-349. 2015
  • The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review.  21:332-341. 2015
  • The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review.  21:305-317. 2015
  • Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.  21:678-688. 2015
  • Composite end points to assess delay of disability progression by MS treatments.  20:1494-1501. 2014
  • Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: Report from the US Pediatric Multiple Sclerosis Network.  20:1502-1510. 2014
  • Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?.  20:1304-1305. 2014
  • "Seeing" in NARCOMS: A look at vision-related quality of life in the NARCOMS registry.  19:953-960. 2013
  • A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.  19:59-68. 2013
  • Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis.  19:891-895. 2013
  • EDSS variability before randomization may limit treatment discovery in primary progressive MS.  19:775-781. 2013
  • The Multiple Sclerosis Intimacy and Sexuality Questionnaire - Re-validation and development of a 15-item version with a large US sample.  19:1197-1203. 2013
  • The magnetic resonance imaging 'rule of five': Predicting the occurrence of relapse.  19:1760-1764. 2013
  • Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures..  18:1074-1080. 2012
  • Examining sleep, fatigue, and daytime sleepiness in pediatric multiple sclerosis patients.  18:481-488. 2012
  • Statistical cures and other fallacies.  18:387-390. 2012
  • Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis.  17:1122-1129. 2011
  • Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis.  17:1464-1471. 2011
  • Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium.  17:725-733. 2011
  • Assessing changes in relapse rates in multiple sclerosis.  16:1414-1421. 2010
  • Composite MRI scores improve correlation with EDSS in multiple sclerosis.  16:1117-1125. 2010
  • Modeling lesion counts in multiple sclerosis when patients have been selected for baseline activity.  16:926-934. 2010
  • The measurement of upper extremity learned nonuse in progressive multiple sclerosis.  16:1018-1019. 2010
  • Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint.  16:840-847. 2010
  • Reproducibility of high-resolution optical coherence tomography in multiple sclerosis.  16:829-839. 2010
  • Evidence of treatment benefit: Is seeing believing or obfuscation by statistics?.  15:1251-1252. 2009
  • Measuring up rates for adverse health behaviors in multiple sclerosis: The need for action.  15:648. 2009
  • Proof of concept studies for tissue-protective agents in multiple sclerosis.  15:542-546. 2009
  • Retinal architecture predicts pupillary reflex metrics in MS.  15:479-486. 2009
  • The burden of mental comorbidity in multiple sclerosis: Frequent, underdiagnosed, and undertreated.  15:385-392. 2009
  • High frequency of adverse health behaviors in multiple sclerosis.  15:105-113. 2009
  • Comorbidity, socioeconomic status and multiple sclerosis.  14:1091-1098. 2008
  • Constraint-Induced Movement therapy can improve hemiparetic progressive multiple sclerosis. Preliminary findings.  14:992-994. 2008
  • Mental health co-morbidities in pediatric multiple sclerosis.  14:S261-S261. 2008
  • Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses.  14:770-778. 2008
  • Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data..  14:370-382. 2008
  • Validation of the NARCOMS registry: Diagnosis.  13:770-775. 2007
  • Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis.  12:526-532. 2006
  • Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: Results from the IMPACT study.  12:180-186. 2006
  • Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.  11:626-634. 2005
  • A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.  11:585-591. 2005
  • Validation of the NARCOMS Registry: Fatique assessment.  11:583-584. 2005
  • The Goldman Consensus statement on depression in multiple sclerosis.  11:328-337. 2005
  • Validation of the NARCOMS registry: Pain assessment.  11:338-342. 2005
  • Clinical characteristics of progressive relapsing multiple sclerosis.  10:451-454. 2004
  • The MS Co-Operative Research (MS-CORE) group: An alternate approach to fostering multicenter studies [1].  10:332-333. 2004
  • The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.  10:55-60. 2004
  • The PROMiSe trial: Baseline data review and progress report.  10. 2004
  • Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis.  9:289-292. 2003
  • Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.  9:1-5. 2003
  • Metabolic differences between multiple sclerosis subtypes measured by quantitative MR spectroscopy.  8:200-206. 2002
  • The Multiple Sclerosis Functional Composite: A new clinical outcome measure for multiple sclerosis trials.  8:359-365. 2002
  • Modelling new enhancing MRI lesion counts in multiple sclerosis.  7:298-304. 2001
  • Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI.  6:312-316. 2000
  • New low-contrast vision charts: Reliability and test characteristics in patients with multiple sclerosis.  6:163-171. 2000
  • Relationship between brain atrophy and disability: An 8-year follow-up study of multiple sclerosis patients.  6:373-377. 2000
  • Self-reported visual dysfunction in multiple sclerosis: Results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25).  6:382-385. 2000
  • The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force..  5:244-250. 1999
  • Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease.  5:335-341. 1999
  • Clinical outcomes assessment in multiple sclerosis: Part II.  2:247-248. 1996
  • International Standard Serial Number (issn)

  • 1352-4585
  • Electronic International Standard Serial Number (eissn)

  • 1477-0970